@article {2243,
	title = {Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer{\textquoteright}s disease},
	journal = {Dalton Transactions},
	number = {45},
	year = {2008},
	note = {ISI Document Delivery No.: 371METimes Cited: 5Cited Reference Count: 29Scott, Lauren E. Page, Brent D. G. Patrick, Brian O. Orvig, Chris},
	pages = {6364-6367},
	type = {Article},
	abstract = {Selective design modifications of specifically substituted 3-hydroxy-4(1H)-pyridinones show possibly advantageous ring freedom while maintaining metal-binding ability and antioxidant capacity, moving toward an efficient potential treatment for Alzheimer{\textquoteright}s disease.},
	keywords = {aluminum, BLOOD-BRAIN-BARRIER, COMPLEXES, DISORDERS, DIVALENT, IRON CHELATORS, PENETRATION, STABILITIES, therapy, TRIVALENT METAL-IONS},
	isbn = {1477-9226},
	url = {<Go to ISI>://000260834600005},
	author = {Scott, L. E. and Page, B. D. G. and Patrick, B. O. and Orvig, Chris}
}
@article {2953,
	title = {PHARMACOKINETICS AND DISTRIBUTION OF TRIS(MALTOLATO)ALUMINUM(III) INTO THE CENTRAL-NERVOUS-SYSTEM},
	journal = {Neurotoxicology},
	volume = {15},
	number = {2},
	year = {1994},
	note = {ISI Document Delivery No.: PB305Times Cited: 4Cited Reference Count: 37},
	month = {Sum},
	pages = {371-378},
	type = {Article},
	abstract = {The maltolate compound of aluminum (Al), tris(maltolato)aluminum(III), has been demonstrated to be quite toxic after central administration and in cell cultures. However, reports of peripheral Al-maltolate administration in vivo demonstrated un impressive neurological effects. We found no reports of Al-maltolate pharmacokinetics or its distribution into the central nervous system (CNS) after systemic administration. In the present study, we evaluated Al pharmacokinetics in serum and Al distribution into brain extracellular fluid (ECF) in rats following Al-maltolate administration. The pharmacokinetic studies revealed that systemic clearance, elimination half-life and mean residence time were 42 (+/- 5) ml/hr/kg, 2.2 (+/- 0.5) hr and 3.1 (+/- 0.7) hr [mean+/-SD), respectively. The steady state volume of distribution (V-ss) for Al-maltolate was 130 ml/kg. This V-ss suggests that Al-maltolate may exhibit limited distribution outside the vascular compartment, which is estimated to be approximate to 80 ml/kg in these rats. Previously, we used microdialysis (MD) probes to assess Al-citrate distribution into the CNS. MD was utilized in the present study to evaluate the CNS distribution of Al as a result of Al-maltolate administration. MD probes were implanted into the frontal cortex (FC) and jugular vein to sample Al from brain and blood ECF, respectively. Al was not measurable in FC MD probe dialysates after a 0.5 mmol/kg Al (as maltolate) bolus, but could be measured after steady state blood and brain ECF Al concentrations had been achieved. The Al brain/blood ra tio calculated from Al-maltolate steady state brain and blood MD samples was 0.04, significantly less than those calculated for other Al salts at equimolar Al doses. The present study suggests that unless it is administered centrally, Al-maltolate might render minimal neurological insult because of its minimal permeation into brain extracellular space. (C) 1994 Intox Press, Inc.},
	keywords = {ALUMINUM MALTOL, ALUMINUM NEUROTOXICITY, ALUMINUM PHARMACOKINETICS, ALUMINUM-MALTOLATE, BLOOD-BRAIN-BARRIER, COMPLEXES, DIALYSIS, ENCEPHALOPATHY, EQUILIBRIUM, gallium, INVIVO MICRODIALYSIS, MICRODIALYSIS, permeability, RABBITS, SERUM},
	isbn = {0161-813X},
	url = {<Go to ISI>://A1994PB30500014},
	author = {Allen, D. D. and Orvig, Chris and Yokel, R. A.}
}
